MiNK Therapeutics, Inc. Convertible Notes Payable, Current
MiNK Therapeutics, Inc. (INKT) had Convertible Notes Payable, Current of $65.42 million as of 2021-09-30, per its 10-Q filed 2021-11-29.
Discontinued › Balance Sheet › Liabilities
us-gaap:ConvertibleNotesPayableCurrent · last filed 2021-11-29
- 2021-09-30: Convertible Notes Payable, Current $65.42M.
| Period end | Convertible Notes Payable, Current |
|---|---|
| 2021-09-30 | $65.42M 10-Q · filed 2021-11-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |